Hana Pharma reports strong Q1 profit growth driven by 505(b)(2) drug portfolio

Hana Pharma reported a 70% year-over-year profit increase in Q1 2026, with EPS at NT$0.46, driven by its 505(b)(2) new drug portfolio. The company's shift towards 505(b)(2) drugs, now comprising over 40% of revenue, boosted Q1 sales by 16% to NT$209 million. This optimization is largely due to strong performance from its multiple sclerosis drug, Tascenso. Hana Pharma also anticipates revenue growth from its leukemia drug, Phyrago, and has multiple new drug candidates in development, aiming for increased revenue stability and product diversity.